Drug combinations key in treating neurodegenerative diseases

January 30, 2009

Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases, Medical College of Georgia researchers say.

Drugs that protect neurons, for example, can be used with those targeting memory to make real progress in treating diseases such as Alzheimer's, says Dr. Jerry Buccafusco, founding director of the MCG Alzheimer's Research Center.

"We realize that with neurodegenerative diseases there will not be one magic bullet," Dr. Buccafusco says. "Developing new therapeutics will require an attack on many different levels. But, right now, there are no FDA-approved compounds out there that are significantly disease-modifying. We're at the point where we're just getting to that."

His review of trends in pharmacological research of neurodegenerative diseases is the featured article in the January issue of NeuroTherapeutics, the journal of the American Society for Experimental NeuroTherapeutics.

Alzheimer's treatment, for instance, should combine molecules that protect neurons from plaque buildup with approved therapies like cholinesterase inhibitors, which treat cognition and memory loss, Dr. Buccafusco says.

Dr. Buccafusco also cited several novel drug candidates developed at the MCG Alzheimer's Research Center, including two molecules prevent cell death in the brain and improve cognition, reaction time and attention.

"What we have to do now is look at drugs that have already been developed to address very specific disease targets and come up with new ways to combine constituent groups of active molecules into a single therapeutic agent," Dr. Buccafusco says. "Drugs should target more than one particular molecular structure and molecular receptor in the central nervous system. The technology is available to design molecules that have multiple properties all in one package. This approach could represent a new frontier for pharmacology."

Advantages to multi-functional drug compounds, he says, include fewer side effects.

Source: Medical College of Georgia

Explore further: CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL

Related Stories

Parkinson's disease linked to microbiome

December 1, 2016

Caltech scientists have discovered for the first time a functional link between bacteria in the intestines and Parkinson's disease (PD). The researchers show that changes in the composition of gut bacterial populations—or ...

Recommended for you

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

Flu forecasts successful on neighborhood level

November 30, 2016

Scientists at Columbia University's Mailman School of Public Health developed a computer model to predict the onset, duration, and magnitude of influenza outbreaks for New York City boroughs and neighborhoods. They found ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Feb 01, 2009
This is great but one has to remember what was not said and the real driving force behind this work: "Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases... and extending the earning power of a variety of older drugs for big pharma.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.